155179-21-8
155179-21-8 structure
- Name: vanicoside B
- Chemical Name: [(2R,3R,4S,5R)-3-hydroxy-4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-5-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxyoxolan-2-yl]methyl (E)-3-(
- CAS Number: 155179-21-8
- Molecular Formula: C49H48O20
- Molecular Weight: 956.893
- Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
- Create Date: 2017-04-11 22:43:34
- Modify Date: 2024-01-20 16:06:39
-
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis[1][2].
| Name | [(2R,3R,4S,5R)-3-hydroxy-4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-5-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxyoxolan-2-yl]methyl (E)-3-( |
|---|---|
| Synonyms |
[(2R,3R,4S,5R)-3-hydroxy-4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-5-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]-5-[(2R,3R,4S,5S,6R)-3,4,5-trihy
1,3,6-Tris-O-[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]-β-D-fructofuranosyl 6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoyl]-α-D-glucopyranoside α-D-glucopyranoside, 1,3,6-tris-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-β-D-fructofuranosyl 6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propen-1-yl]- 1,3,6-Tris-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-β-D-fructofuranosyl 6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-α-D-glucopyranoside |
| Description | Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CDK3 STAT3 |
| In Vitro | 钒苷 B (2.5-20 μM; 72 h) 对三阴性乳腺癌 (TNBC) MDA-MB-231 和 HCC38 癌细胞具有抗增殖活性[1]。 钒苷 B (2.5-20 μM; 72 h, 14 d 和 72 h) 抑制 TNBC 细胞的细胞活力、集落形成，干扰细胞周期[1]。 钒苷 B (2.5-10 μM; 48 h) 降低了 p-STAT1，p-STAT3 和 p-S6 的蛋白水平，并通过调节 Skp2-p27 系列蛋白表达而诱导 TNBC 细胞凋亡[1]。 Western Blot Analysis[1] Cell Line: MDA-MB-231 cells and HCC38 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 48 hours Result: Increased cleaved PARP, and p27 protein expressions, but decreased Skp2 protein level. Suppressed CDK8 target genes and the expression of EMT-associated proteins. Suppressed the expression of the cell proliferation marker Ki-67 in tumor tissues, also significantly suppressed the expressions of p-STAT1 (S727) and AXL. Cell Cycle Analysis[1] Cell Line: MDA-MB-231 cells and HCC38 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 72 hours Result: Inhibited cell cycle at sub-G1 phase. |
| In Vivo | 钒苷 B (5 mg/kg 或 20 mg/kg; 腹腔注射; 每周 3 次, 共 4 周) 抑制 MDAMB-231 细胞移植的小鼠模型中的肿瘤生长[1]。 Animal Model: MDA-MB-231 cell-implanted xenograft mouse model[1] Dosage: 5 mg/kg, 20 mg/kg Administration: Intraperitoneal injection; 3 times per week over 4 weeks Result: Significantly reduced tumor volumes at 5 mg/kg and 20 mg/kg by 53.85% and 65.72%, respectively. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 1165.0±65.0 °C at 760 mmHg |
| Melting Point | 157-159 °C |
| Molecular Formula | C49H48O20 |
| Molecular Weight | 956.893 |
| Flash Point | 339.6±27.8 °C |
| Exact Mass | 956.273865 |
| PSA | 303.96000 |
| LogP | 7.30 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.695 |